AGIO250117P35000
- 1.95
- 0.000.00%
Agios Pharmaceuticals Newsroom
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Agios Pharmaceuticals Analyst Ratings
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $75
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $53
RBC Capital Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Agios Pharma (AGIO) Receives a Buy From Piper Sandler
Agios Pharmaceuticals Initiated at Sector Outperform by Scotiabank
Agios Pharmaceuticals Price Target Announced at $51.00/Share by Scotiabank
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Raymond James Upgrades Agios Pharmaceuticals(AGIO.US) to Buy Rating, Announces Target Price $51